{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-101737","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.811485+00:00","generated_at":"2026-05-17T02:33:50.445956+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Citius Oncology corporate presentation confirms LYMPHIR launch in Q4 2025; $400M+ market","bullets":["LYMPHIR (denileukin diftitox) FDA-approved Aug 2024 for relapsed/refractory CTCL; first new systemic therapy since 2018.","Commercial launch readiness nearing completion; ~$90M invested to date, 12-18 month inventory manufactured.","New permanent J-code (J9161) secured; NCCN guidelines inclusion; sales force hiring underway.","Clinical data: 36% ORR (9% CR, 27% PR), median 1.4 months to response, 6.5 months median duration of response.","Ongoing combo studies: with KEYTRUDA (27% ORR in solid tumors) and CAR-T; prelim data expected Q4 2025/Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-101737","json":"https://secwatch.observer/filing/0001213900-25-101737.json","markdown":"https://secwatch.observer/filing/0001213900-25-101737.md","text":"https://secwatch.observer/filing/0001213900-25-101737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025101737/0001213900-25-101737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025101737/ea0262328-8k_citiusonc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:33:50.445956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}